Proteome Sciences PLC 2019 AR2
The report outlines Proteome Sciences plc's financial and operational performance for the year ended December 31, 2019. The company achieved its first operational profit, driven by strong growth in licensing and service revenues, particularly from its isobaric tandem mass tag (TMT) sales. Key developments included the launch of the 16plex TMTpro reagents and the application of its proprietary TMTcalibrator biomarker discovery workflow in clinical studies. Despite potential disruptions from the COVID-19 pandemic, the company entered 2020 with a strong order book and a positive financial outlook.
Company: Proteome Sciences PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2019
Type: AR2
Pages: 82
Back to company
Proteome Sciences PLC
Report And Financial Statements
The report outlines Proteome Sciences plc's financial and operational performance for the year ended December 31, 2019. The company achieved its first operational profit, driven by strong growth in licensing and service revenues, particularly from its isobaric tandem mass tag (TMT) sales. Key developments included the launch of the 16plex TMTpro reagents and the application of its proprietary TMTcalibrator biomarker discovery workflow in clinical studies. Despite potential disruptions from the COVID-19 pandemic, the company entered 2020 with a strong order book and a positive financial outlook.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees